Clinical trials: Rosuvastatin
Diabetes Mellitus Type 2, Crestor, Rosuvastatin
DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines
The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.
- Conditions
- Diabetes Mellitus Type 2, Crestor, Rosuvastatin, LDL Cholesterol, Observational
- Trial name
- NCT00233649
- Where
- 222 sites in Netherlands
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
COVID-19
Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects
A Drug-Drug Interaction study to assess the effects of EDP-235 on the Pharmacokinetics and Safety of midazolam, caffeine and rosuvastatin.
- Trial name
- NCT05594615
- Testing
- EDP-235, Midazolam, Rosuvastatin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Hypercholesterolemia
The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients with Primary Hypercholesterolemia
- Trial name
- NCT03288038
- Testing
- Rosuvastatin, Ezetimibe
- Where
- 20 sites in South Korea
- Volunteers
- 382 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Hypercholesterolemia
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)
- Trial name
- NCT00240279
- Testing
- Rosuvastatin, aortic pulse wave velocity measurements
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Drug Drug Interaction
Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid
The drug-drug interaction study had been designed to investigate the effect of ZSP1273 on the pharmacokinetics of digoxin, Rosuvastatin and the effect of Itraconazole and Probenecid on the pharmacokinetics of ZSP1273
- Trial name
- NCT05954624
- Testing
- Digoxin, Rosuvastatin, ZSP1273
- Where
- China
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Hepatitis C Virus
TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the single-dose pharmacokinetics of digoxin or rosuvastatin , and the effect of a single dose of digoxin or rosuvastatin on the…
- Trial name
- NCT01288742
- Testing
- Rosuvastatin, TMC435, Digoxin
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hypercholesterolemia
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen.
- Trial name
- NCT01926782
- Testing
- Alirocumab, Statin
- Where
- 83 sites in United States, Bulgaria and 6 more
- Volunteers
- 803 people
- Sponsor
- Regeneron Pharmaceuticals
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
An open-label, randomized, single-dose, 2X3X3 partial replicate, crossover study to compare the pharmacokinetics and safety between a fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a fixed…
- Trial name
- NCT02995720
- Testing
- Fimasartan/Amlodipine combination drug, Rosuvastatin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Healthy
DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple-dose LX4211 400 mg (2 × 200-mg tablets qd × 7 days) on the PK of single-dose…
- Trial name
- NCT02300363
- Testing
- Treatment A (rosuvastatin), Treatment B (LX4211), Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Hypercholesterolemia
A Study of LY3015014 in Participants With High Cholesterol
This study is designed to define the amount and duration of cholesterol lowering and to assess the safety and tolerability of different dose regimens of LY3015014 in participants with high cholesterol.
- Trial name
- NCT01890967
- Testing
- LY3015014, Statin, Ezetimibe
- Where
- 49 sites in United States, Canada and 6 more
- Volunteers
- 527 people
- Sponsor
- Eli Lilly and Company
Intracerebral Hemorrhage
Statins in Patients With Spontaneous Intracerebral Hemorrhage
The relation between improvement in results of treating spontaneous intracerebral hemorrhage (SICH) and the application of statins has been subject to numerous analyses, and yet still remains debatable.
- Trial name
- NCT06094244
- Testing
- Atorvastatin, Rosuvastatin, No drugs
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- Pomeranian Medical University Szczecin
Healthy
DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)
The primary objective of this trial is to investigate the relative bioavailability of rosuvastatin when given alone (Reference treatment, R) compared to when given together with one of the three different doses of metformin (10…
- Trial name
- NCT02574845
- Testing
- Rosuvastatin, Metformin HCl, Furosemide
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
ST-segment Elevation AMI
Efficacy of Early Intensive ROsuvastatin Therapy in Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention (the ROSEMARY Trial)
Objectives: An investigator-initiated, double-blind, randomized, placebo-controlled, multi-center study to evaluate the efficacy of early intensive rosuvastatin therapy (rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI…
- Trial name
- NCT01153334
- Testing
- Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Yonsei University
Hypertension, Cardiovascular Risk Factors
Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve
In ASCOT study, lipid lowering with a statin provided additional beneficial effects in hypertensive patients with average levels of serum total cholesterol.
- Trial name
- RESERVE (NCT01490398)
- Testing
- Rosuvastatin
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Asan Medical Center
Cisplatin Adverse Reaction
Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity
Cisplatin is an effective anti-cancer drug for the treatment of many solid tumors in humans. Although the clinical response to cisplatin chemotherapy is encouraging, the nephrotoxicity and ototoxicity of the drug makes it…
- Trial name
- NCT04817904
- Testing
- Rosuvastatin 10mg
- Where
- Egypt
- Volunteers
- 65 people
- Sponsor
- Cairo University
Wounds and Injuries, Venous Thromboembolism
STAT-STatin and Aspirin in Trauma
This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial examining the efficacy of statins and aspirin in the reduction of acute lung injury and venous thromboembolism in patients with…
- Trial name
- STAT (NCT02901067)
- Testing
- Aspirin and Rosuvastatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Denver Health and Hospital Authority
Nephropathy
A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).
The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.
- Trial name
- CLEAR-CIN (NCT02737319)
- Testing
- Rosuvastatin
- Where
- Brazil
- Volunteers
- 493 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
HIV Infections, Cardiovascular Disease
Effect of Rosuvastatin on Endothelial Function
Rosuvastatin belongs to a class of medications commonly called "statins" which are medications given for high low density lipoprotein (LDL) 'bad' cholesterol to prevent atherosclerosis (hardening of blood vessels) and lower risk…
- Trial name
- NCT00986999
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Hawaii
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants
Researchers are looking for a better way to treat people who have symptoms caused by hormonal changes, like those that happen in women during menopause. These symptoms can include vasomotor symptoms.
- Trial name
- NCT04889287
- Testing
- Elinzanetant (BAY3427080), Rosuvastatin
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Hepatitis B
A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers
This is a drug-drug interaction study conducted in healthy volunteers to evaluate the effect of HRS5091 on CYP3A4, CYP2C9, CYP2C19, P-gp, BCRP and OATP1B1, using midazolam, s-warfarin, omeprazole, digoxin and rosuvastatin as…
- Trial name
- NCT05273775
- Testing
- HRS5091 Tablets, Midazolam Maleate Tablets, Warfarin Sodium Tablets
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.